Join
Live feed
·
INSIDERFilingvia Quantisnow
Alnylam Pharmaceuticals Inc. logo

CSO & EVP, Head of Research Fitzgerald Kevin Joseph was granted 3,688 shares and sold $1,051,773 worth of shares (3,250 units at $323.62), increasing direct ownership by 2% to 21,860 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ALNY (Alnylam Pharmaceuticals Inc.) and more on Quantisnow.